A critical review of the synergistic potential of targeting p53 and CAR T cell therapy in cancer treatment.

Cancer remains a leading cause of mortality worldwide. Extensive research is underway to discover appropriate therapeutic interventions for this disease. One such emerging approach involves the development of targeted drugs, including p53-targeted drugs and chimeric antigen receptor (CAR) T cell therapy. These therapies are the most effective for the treatment of cancer. Both are advantageous when used alone in the treatment of cancer; however, they have certain limitations. Therefore, it has been discovered that the combination of CAR T cells along p53-targeted therapy is beneficial against tumor cells. This review describes an in-depth analysis of both p53-targeted therapies and CAR T cell therapy, scrutinizing their mechanisms and clinical applications, and exploring the synergistic potential of both p53-Targeted Therapies and CAR T cell therapies. Furthermore, to provide a comprehensive consideration of their combined efficacy, a review discusses how the intermingling of CAR T cell therapy and p53-targeted medicines can lead to therapeutic conclusions. Furthermore, it also provides ample evidence on the development, challenges and forthcoming guidelines for both CAR T cell therapies and p53-targeted therapies, making it a vital resource for researchers. Furthermore, the molecular basis for how p53 controls the development and process of numerous components of the tumor microenvironment is described, along with the difficulties that combination therapy can provide, such as tumor heterogeneity, immune evasion, and potential side effects. This review offers valuable information on the potential synergies between p53-targeted medicines and CAR T cell remedies to produce more effective and enduring cancer management by closely examining preclinical and clinical research.